A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Trial Profile

A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs IMM 124E (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immuron
  • Most Recent Events

    • 19 Sep 2017 According to an Immuron media release, this study is being led by Dr. Arun Sanyal and is expected to yield top-line results in the fourth quarter (Q4) of 2017.
    • 10 Jul 2017 According to an Immuron media release, 133 patients are enrolled in the study and the pre-planned analysis was performed after 80 subjects completed the treatment.
    • 10 Jul 2017 Interim results published in the Immuron Limited media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top